

PPD® – Advancing Cell and Gene Therapy Drug Development



Emerging technologies have driven cell and gene therapies to the forefront of healthcare, addressing a growing number of disease conditions including rare diseases with unmet medical needs.

CGT trials are long, incredibly complex, and riddled with unknowns, that is why advancing development in these areas requires special expertise and the ability to tailor services across all stages of drug development.

PPD has deep experience partnering with clients to advance development of their cell and gene therapy trials across numerous indications and all development phases.

Extensive experience in oncology and hematology cell therapy

PPD's relevant experience over the past 5 years



598 Oncology Studies
102,000+ patients
22,000+ sites



83 Hematology Studies
11,000+ patients
3,500+ sites



167 I/O Studies
33,000+ patients
8,000+ sites



137 CGT Studies
including **adoptive cell**
therapy studies

PPD cell and gene therapy experience

200+

Projects

Spanning
all stages of
development

100%

of marketed
transformative
advanced
therapies
support

74+

successful
clinical trial
submissions

Supported 17 of the top 20 top-selling drugs and one of the most published HEOR organizations in the world

PPD's experienced cross functional teams support nearly every stage of development for advanced therapies



Product development and
regulatory strategy



Early phase through
post-approval solutions



Cross-therapeutic expertise



Global site and patient access



CGT specialized
laboratory support



Partnerships with CGT
therapy logistics vendors



CGT logistics coordinator team



Market access, real-world
evidence and value assessment



Learn more about how we can move your cell and gene therapy clinical development program forward.